Vilified for high drug prices, what does the profitability of major US pharma companies look like?
Health care is a human right, not a privilege, global policymakers like to underscore. But in practice in the United States, affordability is one of the most crucial hurdles to accessing care. As the clarion call to lower US drug prices hits deafening heights, a new study suggests that major drugmakers aren’t necessarily raking in more profits than other industries that also depend on science and technology to develop their offerings.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 84,700+ biopharma pros reading Endpoints daily — and it's free.